Navigation Links
Multiple deaths forces cancer trial to be called off

Cell Therapeutics a biotechnology firm based in Seattle has called off further enrollment for the clinical trial it had initiated early this year following the untimely deaths// of few of the patients who were participating in the clinical trial to prove the efficacy of the cancer drug Xyotax.

The CEO of the company James Bianco has reiterated that the deaths of the volunteer s who were cancer patients do not seem to have been triggered of by any kind of toxic effect of the drug Xyotax. He declined to divulge how many patients had actually succumbed to death after the clinical tests were initiated .However he did admit that more women have died from lung cancer in the group that were being given the drug than the group that were put on a standard chemotherapy drug.

The deaths have been certified to have been caused simply because of progression of the lung cancer. Most of the patients participating suffered from advanced cancer. The probability of the clinical tests progressing now is bleak until the data relating to present deaths are studied which would be anything more than six months. This could mean severe financial setbacks for the company.

This clinical trial which had been termed as Pioneer was unique in having enrolled only women who were suffering from lung cancer. It was publicized in a big way with enrollment made at 170 medical centers globally last April, and had planned to study about 600 patients to prove the efficacy of Xyotax in increasing the life span of patients with lung cancer using a regularly used chemotherapy agent coupled with a polymer which is supposed to help in making the it more user friendly.

The same drug in previous tests conducted last year failed to prove itself in improving survival rates in general but showed significant benefits among women. The company has announced that once the study resumes women normal estrogen levels who had already enrolled would be welcome to benefit from tr ials with Xyotax.

Incidentally this company had conducted a similar trial way back in 2003 when it was prematurely halted when deaths of patients were reported with a sudden fall of white blood cells in their bodies owing to drug toxicity. This time around the drug dosage and concentration was severely tapered to avoid toxicity.
MST
'"/>




Related medicine news :

1. Naked DNA Vaccination May Conquer Arthritis and Multiple Sclerosis
2. Multiple organ disease cured by genes
3. Adult stem cells in treatment for Multiple sclerosis (MS)
4. Life Quality For Patients With Multiple Sclerosis
5. Effective Pain Relief For Patients Suffering From Multiple Sclerosis
6. The Link Between Hepatitis B Vaccine And Multiple Sclerosis Questioned
7. Hope For Patients With Multiple Sclerosis
8. Individuals Born In May At A Higher Risk Of Developing Multiple Sclerosis
9. Debating The Link Between Sex Hormones And Multiple Sclerosis
10. Warning Issued by FDA on consumption of the drug Tysabri used to treat Multiple Sclerosis
11. Decreasing Multiple Births By Single Embryo Transfers
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/9/2016)... ... December 09, 2016 , ... MEDI+SIGN®, ... announced today that a new solution for Emergency Departments (ED) has been added ... space in Emergency Department examination rooms, and with a simplified pallet of information ...
(Date:12/8/2016)... ... 08, 2016 , ... After enjoying record-breaking attendance at its ... its 33rd Annual Issues & Research Conference, March 2-3, 2017, at the ... conference is “Persistent Challenges and New Opportunities: Using Research to Accelerate the Dialogue." ...
(Date:12/8/2016)... Plainsboro, NJ (PRWEB) , ... December 08, 2016 , ... ... patients, cancer centers and advocacy groups, has aligned with Upstage Lung Cancer in efforts ... In making the announcement, Michael J. Hennessy, Jr said, “CURE Media Group is honored ...
(Date:12/8/2016)... ... December 08, 2016 , ... Launching of ... Unified Instance Manager architecture, meeting the needs of multichannel growth and doubling ... unattended auto-dialing system without agents, Presence Robodialer, provides greater operational capacity, administrative ...
(Date:12/8/2016)... ... December 08, 2016 , ... Today’s patients are encouraged ... in mind, SIGVARIS has created a new line of anti-embolism stockings to help ... provide the benefits of graduated compression when transitioning from recovery to early rehabilitation. ...
Breaking Medicine News(10 mins):
(Date:12/9/2016)... Dec 9, 2016 Research and Markets ... 2016-2020" report to their offering. ... The report forecasts the global optical transceiver ... 2016-2020. The report covers the present scenario and ... To calculate the market size, the report considers the revenue generated ...
(Date:12/9/2016)... Dec. 9, 2016  Harmar Mobility, LLC announced today that Steven ... of the Board of Directors. Photo - http://photos.prnewswire.com/prnh/20161209/447552 ... ... Mr. Dawson,s executive career includes ... across a variety of industries. He brings to the company deep ...
(Date:12/9/2016)... Dec. 9, 2016 aTyr Pharma, Inc. (Nasdaq: ... of Physiocrine-based therapeutics to address severe, rare diseases, today announced that ... BMO Prescriptions for Success Healthcare Conference at the InterContinental Barclay Hotel ... 14, 2016, at 4:20 p.m. ET. About aTyr ... aTyr ...
Breaking Medicine Technology: